Close Menu

NEW YORK – Fulgent Genetics reported after the close of the market on Thursday that its fourth quarter revenues were up sharply year over year.

For the three months ended Dec. 31, 2020 the company reported revenues of $295.0 million, up 35-fold from $8.4 million in Q4 2019. The firm said it delivered 3.2 million billable tests during Q4, approximately 230 times the number of tests in the prior-year period.

Fulgent Chairman and CEO Ming Hsieh said in a statement that the fourth quarter capped a "transformational" year for the Temple City, California-based firm.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.